scholarly journals Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone

Metabolism ◽  
2017 ◽  
Vol 69 ◽  
pp. 143-147 ◽  
Author(s):  
Jenny Pena Dias ◽  
Johannes D. Veldhuis ◽  
Olga Carlson ◽  
Michelle Shardell ◽  
Chee W. Chia ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Serum Concentration ◽  
Aromatase Inhibitor ◽  
Older Men ◽  
Age Related ◽  
Testosterone Gel ◽  
Low Testosterone

scholarly journals Testosterone Therapy for Men With Age-Related Low Testosterone: Tempest in a Teacup

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 471-471
Author(s):  
Shehzad Basaria
Keyword(s):  
Cardiovascular Health ◽  
Serum Testosterone ◽  
Older Men ◽  
Normal Range ◽  
Testosterone Levels ◽  
Age Related ◽  
Calcified Plaque ◽  
Testosterone Gel ◽  
Physical Dysfunction ◽  
Low Testosterone

Abstract Serum testosterone concentrations decrease in men with age, but benefits and risks of raising testosterone levels in older men remain controversial. In the T-Trials, a total of 790 men, age 65 and older, with a serum testosterone concentration of < 275 ng/dL and symptoms of sexual dysfunction, fatigue or physical dysfunction were randomized to either testosterone gel or placebo gel for 1 year. Treatment in the testosterone arm increased serum testosterone levels to the mid-normal range for young men. Testosterone replacement was associated with a significant increase in sexual activity (p<0.001), libido and erectile function. In contrast, there was no improvement in vitality or physical function. Adverse findings included increases in non-calcified plaque formation and a higher rate of prostate events. In sum, testosterone treatment in older men was associated with modest benefits, while the risk on prostate and cardiovascular health remain unclear.

scholarly journals Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters

Andrology ◽  
2016 ◽  
Vol 5 (1) ◽  
pp. 31-40 ◽  
Author(s):  
J.P. Dias ◽  
M. D. Shardell ◽  
O. D. Carlson ◽  
D. Melvin ◽  
G. Caturegli ◽  
...  
Keyword(s):  
Aromatase Inhibitor ◽  
Older Men ◽  
Low Testosterone

scholarly journals Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone

2019 ◽  
Vol 105 (7) ◽  
pp. 2142-2149 ◽  
Author(s):  
Kashif Shaikh ◽  
Susan S Ellenberg ◽  
Rine Nakanishi ◽  
Peter J Snyder ◽  
Juhwan Lee ◽  
...  
Keyword(s):  
Older Men ◽  
Plaque Progression ◽  
Primary Analysis ◽  
Anthropometric Measures ◽  
Predictive Variables ◽  
Testosterone Gel ◽  
Low Testosterone ◽  
Testosterone Effect ◽  
Noncalcified Plaque ◽  
Cardiovascular Biomarkers

Abstract Objective Recent results from the Cardiovascular Trial of the Testosterone Trials showed that testosterone treatment of older men with low testosterone was associated with greater progression of noncalcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the Testosterone Trial. Methods The Cardiovascular part of the trial included 170 men aged 65 years or older with low testosterone. Participants received testosterone gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of cardiovascular risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. Results Of 170 enrollees, 138 (73 testosterone, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio (WHR) (P = 0.0014) indicated that this variable impacted the testosterone effect on NCP volume. The statistical model indicated that for every 0.1 change in the WHR, the testosterone-induced 12-month change in NCP volume increased by 26.96 mm3 (95% confidence interval, 7.72-46.20). Conclusion Among older men with low testosterone treated for 1 year, greater WHR was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.

Benefits and Risks of Testosterone Treatment in Men with Age-Related Decline in Testosterone

2020 ◽  
Vol 72 (1) ◽  
Author(s):  
Marcelo Rodrigues dos Santos ◽  
Shalender Bhasin
Keyword(s):  
Prostate Cancer Risk ◽  
Older Men ◽  
Annual Review ◽  
Publication Date ◽  
Long Term Effects ◽  
Endocrine Society ◽  
Testosterone Treatment ◽  
Testosterone Levels ◽  
Age Related ◽  
Low Testosterone

The substantial increase in life expectancy of men has focused growing attention on quality-of-life issues associated with reproductive aging. Serum total and free testosterone levels in men, after reaching a peak in the second and third decade of life, decline gradually with advancing age. The trajectory of age-related decline is affected by comorbid conditions, adiposity, medications, and genetic factors. Testosterone treatment of older men with low testosterone levels improves overall sexual activity, sexual desire, and erectile function; improves areal and volumetric bone density, as well as estimated bone strength in the spine and the hip; corrects unexplained anemia of aging; increases skeletal muscle mass, strength and power, self-reported mobility, and some measures of physical function; and modestly improves depressive symptoms. The long-term effects of testosterone on major cardiovascular events and prostate cancer risk remain unclear. The Endocrine Society recommends against testosterone therapy of all older men with low testosterone levels but suggests consideration of treatment on an individualized basis in men who have consistently low testosterone levels and symptoms or conditions suggestive of testosterone deficiency. Expected final online publication date for the Annual Review of Medicine, Volume 72 is January 27, 2021. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

Age-Related Low Testosterone

2020 ◽  
Vol 172 (2) ◽  
pp. 151
Author(s):  
E. Victor Adlin
Keyword(s):  
Age Related ◽  
Low Testosterone

scholarly journals Testosterone Attenuates Age-Related Fall in Aerobic Function in Mobility Limited Older Men With Low Testosterone

2016 ◽  
Vol 101 (6) ◽  
pp. 2562-2569 ◽  
Author(s):  
Thomas W. Storer ◽  
Shalender Bhasin ◽  
Thomas G. Travison ◽  
Karol Pencina ◽  
Renee Miciek ◽  
...  
Keyword(s):  
Medical Center ◽  
Exercise Physiology ◽  
Academic Medical Center ◽  
Older Men ◽  
Peak Oxygen Uptake ◽  
Cycle Ergometer ◽  
Aerobic Performance ◽  
Mobility Limitations ◽  
Age Related ◽  
Ergometer Exercise

Abstract Context: Testosterone increases skeletal muscle mass and strength, but the effects of testosterone on aerobic performance in mobility-limited older men have not been evaluated. Objective: To determine the effects of testosterone supplementation on aerobic performance, assessed as peak oxygen uptake (V̇O2peak) and gas exchange lactate threshold (V̇O2θ), during symptom-limited incremental cycle ergometer exercise. Design: Subgroup analysis of the Testosterone in Older Men with Mobility Limitations Trial. Setting: Exercise physiology laboratory in an academic medical center. Participants: Sixty-four mobility-limited men 65 years or older with low total (100–350 ng/dL) or free (<50 pg/dL) testosterone. Interventions: Participants were randomized to receive 100-mg testosterone gel or placebo gel daily for 6 months. Main Outcome Measures: V̇O2peak and V̇O2θ from a symptom-limited cycle exercise test. Results: Mean (SD) baseline V̇O2peak was 20.5 (4.3) and 19.9 (4.7) mL/kg/min for testosterone and placebo, respectively. V̇O2peak increased by 0.83 (2.4) mL/kg/min in testosterone but decreased by −0.89 (2.5) mL/kg/min in placebo (P = .035); between group difference in change in V̇O2peak was significant (P = .006). This 6-month reduction in placebo was greater than the expected −0.4-mL/kg/min/y rate of decline in the general population. V̇O2θ did not change significantly in testosterone but decreased by 1.1 (1.8) mL/kg/min in placebo, P = .011 for between-group comparisons. Hemoglobin increased by 1.0 ± 3.5 and 0.1 ± 0.8 g/dL in testosterone and placebo groups, respectively. Conclusion: Testosterone supplementation in mobility-limited older men increased hemoglobin and attenuated the age-related declines in V̇O2peak and V̇O2θ. Long-term intervention studies are needed to determine the durability of this effect.

Sign in / Sign up

Export Citation Format

Share Document